^(99)锝-亚甲基二膦酸盐治疗类风湿关节炎继发骨质疏松骨痛的疗效分析  

The efficacy analysis of yunke for the treatment of bone pain in secondary osteoporosis due to rheumatoid arthritis

作　　者：库尔班江 木亚赛尔 武丽君 

机构地区：[1]新疆自治区人民医院风湿免疫科,乌鲁木齐830001

出　　处：《中国骨质疏松杂志》2011年第11期1002-1003,1001,共3页Chinese Journal of Osteoporosis

摘　　要：目的观察99锝-亚甲基二磷酸盐注射液(商品名称:云克)治疗类风湿关节炎(Rheumatoidarthritis,RA)继发骨质疏松骨痛的临床疗效方法52例RA继发骨质疏松骨痛的患者给予云克治疗,所有病例用药前及用药15天后根据WHO疼痛分级标准和评定方法进行评定结果52例接受云克治疗的患者中骨痛完全缓解15例,部分缓解23例,轻度缓解9例,无效5例,疼痛有效率为90.3%。疼痛VAS评分用药前6.89、用药后5.1结论经正规治疗,病情相对稳定的类风湿关节炎患者,补足钙剂及维生素D3后,仍有全身酸痛不适,骨密度提示骨质疏松患者加用云克效果更为理想。Objective To observe the clinical efficacy of yunke （methylene diphosphonate, MDP） for the treatment of bone pain in secondary osteoporosis due to rheumatoid arthritis. Methods All 52 secondary osteoporotic patients with bone pain were treated with MDP. Pain before and 15 days after the medicine use in all cases was evaluated according to the WHO standard pain classification. Results The complete remission of bone pain happened in 15 cases among the 52 patients treated with MDP. Partial remission happened in 23 cases, slight remission in 9 cases, and no remission in 5 cases. The effective rate of relieving pain was 90.3%. The VAS scores were 6.89 before medicine use and 5. 1 after medicine use. Conclusion The relative stable rheumatoid arthritis patients can still feel pain in whole body after regular treatment and enough supplement of calcium and vitamin D. Bone mineral density measurement indicates that MDP is a more ideal treatment for osteoporotic patients.

关 键 词：99锝-亚甲基二膦酸盐 类风湿关节炎 继发骨质疏松 骨痛 

分 类 号：R687.3[医药卫生—骨科学]